|
|
|
|
Vol. 53, Issue 6, 1040-1046, June 1998
-Glutamyl
Hydrolase
Wadsworth Center, Division of Molecular Medicine, New York State Department of Health, Albany, New York 12201-0509
| |
Summary |
|---|
|
|
|---|
A previously identified cDNA encoding a human
-glutamyl hydrolase
was expressed in a baculovirus system. The expressed protein had
molecular mass of 37 kDa. Treatment of the protein with PNGase F
produced a protein of molecular mass of 30 kDa, indicating that the
protein contained asparagine-linked glycosylation. Sequence analysis of
the expressed protein indicated that a 24-amino-acid signal peptide had
been removed. A polyclonal antibody to the expressed enzyme was used in
Western blot analysis of partially purified lysates of HL-60 promyeloid
leukemia cells and MCF-7 breast cancer cells. The HL-60 and MCF-7
enzymes appeared as two closely spaced bands with a molecular mass of
37 kDa. Treatment of the HL-60 enzyme with PNGase F produced a protein
with a molecular mass of 30 kDa. The activities of the expressed enzyme
and the enzyme from HL-60 cells were similar on methotrexate
polyglutamates. Methotrexate-
-Glu is a poor substrate for the human
enzyme relative to methotrexate
-Glu2-5. During
hydrolysis of methotrexate-
-Glu4, all possible
pterin-containing cleavage products (methotrexate and
methotrexate-
-Glu1-3) appear. The results demonstrated that the human enzyme cleaves both the ultimate and penultimate
-linkages of methotrexate polyglutamates. Glutamate was released as
either glutamic acid or
-Glu2. Longer chain species of
-Glun>2 were not observed. Inhibition by iodoacetic
acid suggested that both the expressed enzyme and the HL-60 enzyme may
contain a catalytically essential cysteine. These results indicate that
the identified cDNA encodes the intracellular
-glutamyl hydrolase
found in a variety of human tumor cells and that the
baculovirus-expressed enzyme is a suitable model for further structural
and enzymatic studies.
| |
Introduction |
|---|
|
|
|---|
GH
is a key enzyme in the metabolism of folic acid and the pharmacology of
antifolates such as MTX. Folylmonoglutamates or antifolylmonoglutamates
enter cells through specific transport systems. Inside the cell, they
are converted to folylpoly-
-glutamates or
antifolylpoly-
-glutamates by the enzyme FPGS. Glutamate is added
sequentially, yielding chain lengths of five to eight
poly-
-glutamates as the predominant intracellular forms. The
folylpolyglutamates are retained inside the cell and are better
substrates than the monoglutamate for most folate-dependent enzymes. GH
catalyzes the removal of
-linked polyglutamates from these
intracellular folylpolyglutamates to yield folylmonoglutamate
coenzymes. This allows the folylmonoglutamate to be released from the
cell. A similar mechanism is involved in the uptake and metabolism of antifolates such as MTX (Shane, 1995
; Priest and Bunni, 1995
). MTX
polyglutamates are retained inside the cell, while MTX is released. In
rat H35 hepatoma cells in culture, increased levels of GH activity have
been associated with resistance to antifolates such as MTX and
10-propargyl-5,8-dideazafolate and with a reduction in intracellular
polyglutamates of 10-propargyl-5,8-dideazafolate (Rhee et
al., 1993
). Similarly, CCRF-CEM human leukemia cell lines resistant to 5,10-dideaza-5,6,7,8-tetrahydrofolic acid were found to
have lower levels of polyglutamylation due to a decrease in FPGS
activity, with the most resistant cell lines also having an increased
GH level (Pizzorno et al., 1995
). Decreased MTX
polyglutamate formation in the blasts of patients with leukemia has
been associated with resistance to MTX treatment, and the GH/FPGS ratio
was a predictor of MTX polyglutamylation (Longo et al.,
1997
). The balance between the intracellular activities of FPGS and GH
therefore is important both in the cellular maintenance and metabolism
of folic acid and in the antitumor efficacy of antifolates. Despite the
importance of GH in the pharmacodymanics of antifolates and as a
potential therapeutic target, no structural studies have been reported
of the intracellular enzyme or detailed kinetic analyses of
GH-catalyzed polyglutamate hydrolysis using purified enzyme.
In this laboratory, a cDNA for an hGH (folylpolyglutamate hydrolase)
was identified from the expressed sequence tag database and expressed
in Escherichia coli (Yao et al., 1996
). The
identified clones were from human placenta and brain. The gene for hGH
has been located on chromosome 8, region q12.23-13.1 (Yao et
al., 1997
). The full-length protein encoded by the cDNA has a
molecular mass of 36.7 kDa, contains four potential asparagine
glycosylation sites, and was predicted to have a 24-amino-acid signal
peptide (Yao et al., 1996
). Isolation and structural
characterization of intracellular hGH from cells or tissue have not
been carried out. In the current study, the identified cDNA for hGH was
expressed as an active enzyme in a baculovirus system, and the
expressed protein was used to raise a polyclonal antibody. This
antibody was used to characterize the intracellular hGH from HL-60
promyeloid leukemia cells and MCF-7 breast cancer cells. The antibody
also was used to purify the enzyme from HL 60 cells by immmunoaffinity chromatography. The catalytic properties of hGH from the enzyme preparations was studied using MTX polyglutamates containing two to six
-glutamates.
| |
Experimental Procedures |
|---|
|
|
|---|
Materials.
4-NH2-10-CH3-PteGlu1-6
were purchased from Dr. B. Schricks Laboratories (Jona, Switzerland).
Mercaptoethanol, Triton X-100, OPA, and sodium acetate were purchased
from Sigma Chemical (St. Louis, MO). A protease inhibitor cocktail
(Complete) was purchased from Boehringer-Mannheim (Indianapolis, IN).
PNGase F was a gift from Dr. Thomas H. Plummer Jr. (Wadsworth Center, Division of Molecular Medicine, New York State Department of Health, Albany, NY). Octyl
-glucoside was purchased from Pierce (Rockford, IL). Iodoacetic acid was purchased from MCB (Cincinnati, OH).
Construction of the GH transfer vector.
A human EST clone
(Genbank H09442) previously shown to encode hGH (Yao et al.,
1996
) was obtained from Genome Systems (St. Louis, MO). A 1.1-kb DNA
fragment including the entire open reading frame and some 3'-UTR was
amplified from H09442 by polymerase chain reaction and cloned into
pCRII (InVitrogen, San Diego, CA). Orientation was determined by
restriction analysis. The hGH-cDNA, including the leader sequence, was
excised from pCRII using NotI (at the 5'-end) and
KpnI (at the 3'-end). This cDNA fragment was then ligated
into the NotI/KpnI sites of the pVL-1392
baculovirus transfer vector (InVitrogen). The integrity of the cloned
hGH-cDNA was determined by sequencing analysis. Sequencing of this
insert and resequencing of the original cDNA yielded a corrected
sequence in which nucleotides 857 and 858 were A rather than C and
nucleotide 905 was C rather than G. In the 3'-UTR, nucleotide 1065 was
C rather than G. This resulted in reassigning Asn268 to lysine, Pro269
to threonine, and Lys284 to asparagine in the encoded protein. This
final baculovirus transfer vector construct was designated pVL-hGH.
Expression of recombinant hGH in insect cells.
The transfer
vector pVL-hGH (~2 µg) was combined with 0.5 µg of linear
baculovirus DNA (BaculoGold; PharMingen, San Diego, CA) and transfected
into the Sf9 insect cell line using a calcium phosphate precipitate
method modified for insect cells (Guarino and Summers, 1986
). After a
4-hr incubation at 27°, the transfection medium was removed and
replaced with TNM-FH supplemented with 10% fetal bovine serum. Medium
was collected 4 days after transfection. Recombinant virus was
amplified, plaque purified and titered according to King and Possee
(1992)
.
Purification of the baculovirus-expressed hGH.
The pH of the
harvested medium was adjusted to 5.3 with acetic acid. A portion (450 ml) of the medium was diluted to 1.35 liters with deionized water to
lower the ionic strength. The diluted medium consisted of 50 mM mercaptoethanol, 1 mM octyl
-glucoside, and 1 mM EDTA and applied (10 ml/min) to a
column of Protein-Pak CM (2.0 × 10 cm, 40 HR; Waters Division,
Millipore, Milford, MA) equilibrated in 25 mM sodium
acetate containing 50 mM mercaptoethanol, 1 mM
octyl b-glucoside, and 1 mM EDTA. The enzyme was
eluted at a flow rate of 1.5 ml/min with the same buffer containing 500 mM NaCl. Yields of enzyme were ~15 mg/liter of culture
medium.
Preparation of a rabbit polyclonal antibody to the
baculovirus-expressed hGH.
A female rabbit was immunized with 150 µg of the purified expressed hGH. The rabbit then was administered
two additional boosts of 150 µg according to a standard protocol
(Wang et al., 1993a
). The antisera used were from bleeds
after the boosts. Before use, the IgG was purified from the antisera by
ammonium sulfate precipitation and chromatography on Protein A-coupled
Sepharose. The purified antisera could detect 50 ng of the antigen at a
1:100,000 dilution in an enzyme-linked immunoassay.
Isolation of hGH from HL-60 and MCF-7 cell lysates using cation
exchange chromatography.
HL-60 cells were received from culture
and washed three times with RPMI 1640 medium containing no serum. The
washed cells (4 × 108 cells/ml) were lysed
in 50 mM sodium acetate buffer, pH 5.5, containing 50 mM mercaptoethanol and 1% Triton X-100, pH 5.5. The lysate
was dialyzed against 50 mM sodium acetate, 50 mM mercaptoethanol, and 1 mM OBG, pH 5.5, and
centrifuged at 10,000 × g. The dialysed lysate (10 ml)
was applied to a column of CM-52 (1.5 × 18 cm; Whatman; Clifton,
NJ) equilibrated in the dialysis buffer. After washing with the
equilibration buffer, the
-glutamyl hydrolase activity was eluted
with the same buffer containing 1.0 M NaCl. Fractions
containing activity were combined and concentrated using an Amicon
(Beverly, MA) stirred cell with a YM-10 membrane. Semipurified MCF-7
cell lysates were similarly prepared. The lysates were analyzed by
SDS-12.5% PAGE, blotted onto nitrocellulose, and probed with a
1:50,000 dilution of the anti-hGH rabbit antibody. A goat anti-rabbit IgG horesradish peroxidase conjugate (BioRad, Hercules, CA) was used as
secondary antibody, and the blot was developed with an enhanced
chemiluminescence system (ECL Western blotting system; Amersham,
Arlington Heights, IL).
Isolation of hGH from HL-60 lysate using immunoaffinity chromatography. HL-60 cells (4 × 108 cells/ml) were lysed in phosphate-buffered saline plus 1% Triton X-100 containing a cocktail of protease inhibitors (Complete; Boehringer-Mannheim). A portion of lysate (30 ml) was mixed with 5 ml of a 50% slurry of anti-GH-IgG coupled to cyanogen bromide-activated Sepharose 4B, and the mixture was rotated overnight at 4°. The affinity medium was packed in a column (1.5 × 2.5 cm) and washed with 5 ml of phosphate-buffered saline. The elution buffer was then changed to 0.1 M glycine, pH 2.0. Fractions (0.5 ml) were collected into 50 µl of 1 M sodium acetate/1 M mercaptoethanol, pH 5.5. The fractions were analyzed for activity and by Western blot analysis. Fractions containing hGH were pooled and concentrated to two thirds of the original volume.
Treatment of expressed hGH and hGH from HL-60 cells with PNGase
F.
The pH of an aliquot (200 µl) of the pool of purified
expressed hGH was adjusted to 7.4 with 10 µl of 0.1 N
NaOH and 20 µl of 250 mM EDTA added. An aliquot of 10%
SDS solution (10 µl, 0.42% final) was added, and the solution was
placed in a boiling water bath for 3 min. An aliquot of 10% Nonidet
P-40 solution (13 µl, 0.51% final; Pierce) was added, and the
solution was divided into two portions of 50 and 150 µl. An aliquot
(5 µl) of PNGase F solution (0.69 µg/µl) was added to the
150-µl portion, and both solutions were incubated at room temperature
for 48 hr. The solutions were frozen at
20° until they were
analyzed. An aliquot (200 µl) of immunoaffinity-purified hGH from
HL-60 cells was treated similarly. The samples were analyzed by
SDS-12.5% PAGE followed by Western blotting onto nitrocellulose.
Prestained protein molecular mass standards (BioRad) were used to
determine approximate molecular masses on the blot. A 1:10,000 dilution
of the anti-hGH antibody and a goat anti-rabbit IgG alkaline
phosphatase conjugate (BioRad) as secondary antibody were used. The
blot was developed with an alkaline phosphatase conjugate substrate kit
(BioRad) according to the manufacturer's directions.
Enzyme activity assays.
The enzyme activity was measured
using 100 µM MTX polyglutamates
(4-NH2-10-CH3PteGlun)
as substrate in pH 6.0 buffer and incubation at 37° for varying
times. The pterin-containing products were separated by HPLC (Rhee
et al., 1995
) or capillary electrophoresis (Takemura
et al., 1996
). For kinetic studies, the rate was measured as
the disappearance of the substrate. With
4-NH2-10-CH3PteGlu6 and
4-NH2-10-CH3PteGlu5
as substrates, there was the potential for generating products that
would be competing substrates. For this reason,
Vmax rates were measured when no more than
15% of the substrate was used. Under these conditions, 90% of the
hydrolysis products are due to the initial cleavage. The released
glutamic acid and
-glun were derivatized with
orthophthaldehyde and analyzed by HPLC using fluorescence detection
(Wang et al., 1993
).
Amino-terminal analysis of hGH samples.
Amino-terminal amino
acid sequence analysis of expressed proteins was carried out by
blotting onto Immobilon (BioRad), excising the bands of interest, and
sequencing as described previously (Yao et al., 1996a
).
Inhibition of expressed and HL-60 hGH by iodoacetic acid. Solutions (15 µl) of recombinant hGH in either 50 mM NaAc, 50 mM mercaptoethanol, pH 5.5, or 50 mM MES, and 2 mM dithiothreitol, pH 5.5, were incubated at 37° with various concentrations of iodoacetic acid (0-0.5 mM final concentration). At time intervals of 0-120 min, aliquots were removed and diluted 1:49 with 50 mM MES, and 2 mM dithiothreitol, pH 3.65, containing 100 µM 4-NH2-10-CH3PteGlu5. The assay mixtures were incubated for 1 hr at 37°, boiled for 3 min, and analyzed by capillary electrophoresis to determine MTX product distribution. The inhibition of recombinant hGH by 500 µM p-hydroxymercuribenzoate (Sigma Chemical) was measured in a similar way. The inhibition of cation exchange-purified hGH from HL-60 cell lysates was carried out in an identical way, except the dilution of incubation mixture with assay mixture was 1:5 because of lower amounts of enzyme.
| |
Results |
|---|
|
|
|---|
The cDNA was readily expressed in a baculovirus system, and the
expressed protein was partially purified by ion exchange
chromatography. After this purification step, yields of protein were
~15 mg/liter [specific activity, 6.4 nmol of product/µg of
protein/min], and the enzyme appeared on analysis by SDS-PAGE as a
broad band with a molecular mass of 37 kDa and a faint band due to a
baculovirus protein with a molecular mass of 65 kDa (Fig.
1). Amino-terminal analysis of the
expressed enzyme before ion exchange chromatography yielded
Arg25-Pro-His-Gly. This sequence begins with
Arg25 of the encoded amino-acid sequence, confirming a previous
suggestion (Yao et al., 1996
) that the first 24 amino acids
constitute a signal peptide that is removed during processing of the
protein. After ion exchange chromatography, ~80% of the protein had
Gly28 as the amino terminus, presumably due to the action of a
contaminating protease. This proteolysis could be prevented and the
amino terminus maintained as Arg25 by carrying out the purification in
the presence of 1 mM EDTA (data not shown).
|
The baculovirus-expressed enzyme purified by ion exchange
chromatography was used for antibody production. The rabbit polyclonal antibody readily detected the baculovirus-expressed enzyme in a Western
blot assay (Fig. 2, lane 1).
The predicted sequence for the enzyme contains four potential
glycosylation sites (Yao et al., 1996
). After treatment with
the enzyme PNGase F to remove asparagine-linked carbohydrate, the
expressed enzyme migrated as a band with a molecular mass of 30 kDa
(Fig. 2, lane 2), consistent with the calculated molecular
mass of the encoded mature enzyme (33.6 kDa). Lysates of HL-60
promyeloid leukemia cells and MCF-7 breast cancer cells after ion
exchange chromatography then were examined by Western blot analysis to
determine whether the intracellular enzyme corresponded to the protein
encoded by the identified cDNA and the baculovirus-expressed enzyme.
When analyzed by Western blot analysis, both lysates contained an
immunoreactive protein with a molecular mass of 37 kDa. When lysates of
MCF7 and HL-60 cells purified by ion exchange chromatography were
analyzed using Western blotting and a chemiluminescence detection
system, the HL-60 cell and MCF-7 cell hGH proteins could be resolved
into two closely spaced bands rather than a single band (Fig.
3). These two bands were not resolved
when samples were analyzed by Western blotting using an
enzyme-catalyzed color reaction detection system. This may be related
to the higher concentration (1:10,000 dilution) of primary antibody
required in this type of assay. An immunoaffinity chromatography matrix
was prepared by coupling the polyclonal antibody against
baculovirus-expressed hGH to Sepharose 4B. This matrix was used to
purify hGH from HL-60 cell lysates. The enzyme activity was retained on
the column and could be eluted by using a low pH buffer (data not
shown). The pooled fractions had the previously identified 37-kDa band
when analyzed by Western blotting (Fig. 2, lane 3). The
HL-60 cell enzyme when treated with PNGase yielded a protein of
molecular mass of 30 kDa, similar to the baculovirus-expressed enzyme
(Fig. 2, lane 4). The protein with molecular mass of ~53
kDa in Fig. 2 (lanes 3 and 4) seemed to be a contaminant
that was not observed in the ion exchange-purified material (Fig. 3).
|
|
The expressed enzyme was evaluated for its mode of hydrolysis of
4-NH2-10-CH3PteGlu2-6.
Initially, we examined the dependence of the reaction rate on the
concentration of MTX polyglutamates of different glutamate chain
lengths (two to six) (Fig. 4). As shown in Fig. 4,
4-NH2-10-CH3PteGlu2
was a poor substrate for expressed hGH in regard to both
Vmax and enzyme saturation, with the latter
achieved at 400 µM (data not shown). The lack of activity on
4-NH2-10-CH3PteGlu2
corroborates the results of an earlier study that we conducted on a
panel of hGH enzymes secreted by several human tumor cell lines (Rhee
et al., 1995
). The Vmax values for the other substrates decreased in the order
4-NH2-10-CH3PteGlu6 >4-NH2-10-CH3PteGlu4 > 4-NH2-10-CH3PteGlu5 > 4-NH2-10-CH3PteGlu3.
|
In the next experiment, we sought to determine the properties of
appearance of the MTX products during the cleavage of
4-NH2-10-CH3PteGlu3-6. Previous studies (Yao et al., 1996
) had shown that
E. coli-expressed hGH catalyzed the cleavage of
4-NH2-10-CH3PteGlu5,
yielding all possible pteroyl-containing products
(4-NH2-10-CH3PteGlu4,
4-NH2-10-CH3PteGlu3, 4-NH2-10-CH3PteGlu2,
and
4-NH2-10-CH3PteGlu1)
of MTX polyglutamates. The data shown in Fig.
5 are representative of numerous studies that followed the expressed enzyme catalyzed reaction through ~50%
hydrolysis of the particular substrate. In all cases, each intermediate
product appeared. For example, the cleavage of
4-NH2-10-CH3PteGlu6 resulted in the appearance of
4-NH2-10-CH3PteGlu5-1.
An interesting feature of the expressed human enzyme-catalyzed reaction was the more rapid appearance of the product containing two fewer glutamates than the product lacking a single glutamate. This
preferential cleavage occurred in all substrates containing three to
six glutamate residues. A similar result had been observed with
unpurified hGH secreted from human tumor cell lines, but further
studies were not conducted at that time to elucidate the cause (Rhee
et al., 1995
).
|
An analysis of the
-Glu products in a separate experiment revealed
the reason for the results in Fig. 5. All substrates, except
4-NH2-10-CH3PteGlu2,
were hydrolyzed to release both
-Glu2 and
glutamic acid (Table 1). In some cases,
-Glu2 exceeded glutamic acid, which is
consistent with the release of greater amounts of the product
containing MTX polyglutamates with two glutamates removed. These
results clearly demonstrate that the human enzyme expressed in the
baculovirus system catalyzes the hydrolysis of both the ultimate and
penultimate
-Glu linkages. In no case was a
-Glun product found that contains more than
two glutamic acid residues. The partially purified enzymes from MCF-7
and HL-60 cells had the same mechanism of hydrolysis with the release
of
-Glu2 and glutamic acid exclusively (data
not shown).
|
In an additional study, we evaluated the hydrolysis process for the
substrate
4-NH2-10-CH3PteGlu3.
This product analysis is simplified because it yields only two
MTX-containing products (4-NH2-10-CH3PteGlu2
and
4-NH2-10-CH3PteGlu1)
and two
-Glu-containing products (
-Glu2 or
glutamic acid). This substrate also has a relatively high
Vmax value (Fig. 4). The results clearly
show that the primary pterin-containing cleavage product is
4-NH2-10-CH3PteGlu, with
lesser amounts of
4-NH2-10-CH3PteGlu2
(Fig. 6). Consistent with this,
-Glu2 production exceeds that of glutamic
acid, although quantitatively it is not as great as the predominance of
4-NH2-10-CH3PteGlu1 over
4-NH2-10-CH3PteGlu2.
This may be due to the concomitant hydrolysis of
-Glu2, because
-Glu2
is also a substrate for hGH. Replication of the experiment described in
Fig. 6 with hGH from HL-60 and MCF-7 cells and that expressed in
E. coli (Yao et al., 1996
) gave similar results.
|
The baculovirus-expressed hGH was inhibited by iodoacetic acid in a
time- and concentration-dependent manner (Fig.
7). The recombinant enzyme also was
inhibited by p-hydoxymercuribenzoate (500 µM),
suggesting that like the rat enzyme (Yao et al., 1996a
), the
human enzyme may contain a catalytically essential cysteine. The
partially purified hGH from HL-60 lysates also was readily inhibited by
500 µM iodoacetic acid (Fig. 7, inset).
|
| |
Discussion |
|---|
|
|
|---|
A cDNA encoding a human GH was identified previously and expressed
in E. coli (Yao et al., 1996
). This
cDNA has now been expressed in a baculovirus system to yield an active
glycosylated enzyme. Analogous to the rat enzyme (Yao et
al., 1996a
), a 24-amino-acid signal peptide was removed during
protein processing to yield the mature protein. A polyclonal antibody
raised against the baculovirus-expressed enzyme cross-reacted with the
intracellular hGH from HL-60 cells and MCF-7 cells, indicating that the
three proteins were antigenically similar, of similar molecular mass,
and glycosylated on asparagine. The resolution of the HL-60 cell enzyme
and the MCF-7 enzyme into two closely spaced bands when the proteins
were analyzed by Western blotting using chemiluminescent detection is
presumably due to post-translational modification of the proteins.
Further studies will be necessary to determine the nature of this
modification. A similar observation of two protein forms was made with
the rat enzyme (Yao et al., 1996a
). Both the
baculovirus-expressed enzyme and the intracellular enzyme from HL-60
cells were inhibited by iodoacetic acid, suggesting that they both
contained a catalytically essential cysteine.
The human enzyme has been shown to degrade MTX polyglutamates by
removing either the outermost glutamate individually or the two
outermost glutamates together. It has been suggested that because of
the appearance of all possible MTX polyglutamates during the course of
degradation of a long chain MTX polyglutamates, the enzyme could have
been an exopeptidase (Yao et al., 1996
; Waltham et
al., 1997
). Exopeptidase refers to the cleavage of only the
outermost
-linkage. It now seems clear that the situation is more
complex because either of the two outermost
-linkages can be
cleaved. However, we could not detect any evidence for removal of the
more interior linkages because
-Glun with n > z were never found.
In many cases, the MTX polyglutamate product with two fewer glutamates
exceeds the product with one fewer glutamate, and
-Glu2 exceeds glutamic acid. It is somewhat
difficult to quantify this because all products except MTX and
glutamate are substrates. However, the predominance suggests that the
penultimate
-linkage may be favored. If this is so, it may be the
reason
4-NH2-10-CH3PteGlu2 is such a poor substrate. It is clear, however, that more detailed studies on the reaction will be required because the resulting product
profile also contains substrates and presents a very complex problem.
The possibility of ultimate and penultimate
-cleavage was
established by Wang et al. (1986)
with the cellular enzyme
of human jejunal mucosa. They determined that incubation of hGH
preparations with
PteGlu2[14C]Glu liberated
[14C]Glu and
[14C]
-Glu2. However,
they did not examine longer chain polyglutamates or evaluate the
cellular enzymes from other sources. Thus, the current work supports
their initial observation and generalizes to longer chain
polyglutamates and to the GH from other human sources.
The triglutamate derivative makes an interesting model substrate. It
has a high Vmax value, but unlike the
longer chain polyglutamates, it produces only two pterin-containing
products, the monoglutamate and diglutamate. It could be used to
examine tissues for the pattern of cleavage of MTX or folate
polyglutamates. If the appearance of the pteroyl monoglutamate early in
the reaction exceeds that of the diglutamate, it is suggestive of both
-linkages being cleaved. It is very unlikely that the degradation of
4-NH2-10-CH3PteGlu3 proceeds slowly and the product
4-NH2-10-CH3PteGlu2
is cleaved very rapidly to
4-NH2-10-CH3PteGlu, because
4-NH2-10-CH3PteGlu2 is such a poor substrate for hGH (Fig. 4). In these experiments in
which we examined the hydrolysis of
4-NH2-10-CH3PteGlu3,
cleavage of the penultimate
-linkage clearly seems to be favored.
It is possible that hGH from human tissues and cells that have not yet
been examined have different hydrolysis patterns from those we describe
here. Two others that will be particularly interesting are the
membrane-associated hGHs: one from the jejunal brush border (Chandler
et al., 1986
) and one from prostate membrane (Pinto et
al., 1996
). These are distinct from cellular hGH with regard to
sequence and structure. Chandler et al. (1986)
presented
evidence that the jejunal brush border enzyme is an exopeptidase with
PteGlu2[14C]Glu used as
the substrate. The prostate membrane enzyme superficially appears like
an exopeptidase (Pinto et al., 1996
), but
analysis of the
-Glun products has not been
done, nor has pteroyl polyglutamate with labeled glutamate been used as
a substrate. The human enzymes described in this report have similar
physical properties (molecular mass, pH optimum, and essential
sulfhydryl group) to the intracellular human enzyme identified in the
soluble fraction of jejunal mucosa (Reisenauer et al., 1977
;
Wang et al., 1986
) and to the enzyme from human sarcoma
HT-1080 cells (Waltham et al., 1997
).
The role of hGH in determining the therapeutic activity of MTX and
other antifolates has not been determined. Enhancement of hGH activity
in host tissues or inhibition of hGH in target tissues could
potentially enhance the therapeutic index of these drugs. Using
in vitro models of rat and human tumor cells in culture, it
has been demonstrated that elevated GH is associated with reduced antifolate activity (Rhee et al., 1993
; Pizzorno et
al., 1995
). In addition, resistance of human leukemia to MTX has
been associated with high levels of hGH relative to FPGS (Longo
et al., 1997
).
GH-dependent antifolate resistance presents an interesting and complex
case. Antifolate resistance could result from an increase in the amount
of GH enzyme causing greater GH activity, as seems to be the case with
rat H35 hepatoma cell lines (Rhee et al., 1993
). Studies
from this laboratory have shown that the cDNAs for rat and human GH
encode proteins containing leader sequences and consensus
glycosylation sites that result in the enzyme being targeted to the
lysosomes and for secretion (Rhee et al., 1995
; Yao et
al., 1995
). Mutations in any of these sites could result in
altered trafficking of the enzyme. If a mutation caused significant amounts of the enzyme to be rerouted to the cytosol, a dramatic reduction in MTX polyglutamate formation and cytotoxic activity would
result. Hence, a complete understanding of the structure and activity
of GH is required to assess the contribution of GH to the cytotoxicity
of MTX and other antifolates. The baculovirus-expressed human GH seems
to be the same hGH as that found intracellularly in a variety of normal
and abnormal human cell lines and may serve as a model for structural
and kinetic studies aimed at the design of therapeutic inhibitors.
| |
Acknowledgments |
|---|
We gratefully acknowledge the technical assistance of Jean DiNovo and Christopher Macaluso in these studies. Peptide sequencing was provided by the Amino Acid Analyses and Peptide Sequencing Core Facility of the Wadsworth Center. Enzyme purifications were carried out in the Biochemistry Core Facility of the Wadsworth Center. DNA sequencing was carried out in the Molecular Genetics Core Facility of the Wadsworth Center.
| |
Footnotes |
|---|
Received January 13, 1998; Accepted March 2, 1998
This study was supported in part by Grant CA25933 from the National Cancer Institute/National Institutes of Health/Department of Health and Human Services.
Send reprint requests to: Dr. T. J. Ryan, Wadsworth Center, New York State Department of Health, Empire State Plaza, Albany, NY 12201-0509. E-mail: thomas.ryan{at}wadsworth.org
| |
Abbreviations |
|---|
GH,
-glutamyl hydrolase;
MTX, methotrexate;
hGH, human
-glutamyl hydrolase;
FPGS, folylpolyglutamate synthetase;
HPLC, high performance liquid
chromatography;
OPA, o-phthalaldehyde;
OBG, octyl
-D-glucoside;
PteGlun, folylpolyglutamate;
PNGase F, peptide-N4-(N-acetyl-
-glucosaminyl)
asparagine amidase;
SDS, sodium dodecyl sulfate;
PAGE, polyacrylamide
gel electrophoresis.
| |
References |
|---|
|
|
|---|
-Glutamyl hydrolase secreted from human tumour cell lines.
Cell Pharmacol
2:
289-292.
-glutamyl hydrolase activity.
Cancer Res
53:
2227-2230
-Glutamyl hydrolase from human sarcoma HT-1080 cells: characterization and inhibition by glutamine antagonists.
Mol Pharmacol
51:
825-832
-glutamyl hydrolase and poly-
-glutamate.
Adv Enzyme Regul
33:
207-218[Medline].
-glutamyl hydrolase from H35 cells.
Biochim Biophys Acta
1164:
227-235[Medline].
-glutamyl hydrolase: human tissue distribution and chromosome location, in
Chemistry and Biology of Pteridines and Folates (Pfleiderer W and
Rokos H eds) pp 475-478,
Blackwell, Berlin.
-glutamyl hydrolase.
J Biol Chem
271:
8525-8528
-glutamyl hydrolase on folyl and antifolyl polyglutamates in cultured H35 cells.
Mol Phamacol
48:
505-511[Abstract].
-glutamyl hydrolase: cloning and characterization of the enzyme expressed in vitro.
Proc Natl Acad Sci USA
93:
10134-10138This article has been cited by other articles:
![]() |
M. Dolled-Filhart, L. Ryden, M. Cregger, K. Jirstrom, M. Harigopal, R. L. Camp, and D. L. Rimm Classification of breast cancer using genetic algorithms and tissue microarrays. Clin. Cancer Res., November 1, 2006; 12(21): 6459 - 6468. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Orsomando, R. D. de la Garza, B. J. Green, M. Peng, P. A. Rea, T. J. Ryan, J. F. Gregory III, and A. D. Hanson Plant {gamma}-Glutamyl Hydrolases and Folate Polyglutamates: CHARACTERIZATION, COMPARTMENTATION, AND CO-OCCURRENCE IN VACUOLES J. Biol. Chem., August 12, 2005; 280(32): 28877 - 28884. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dervieux, D. Orentas Lein, J. Marcelletti, K. Pischel, K. Smith, M. Walsh, and R. Richerson HPLC Determination of Erythrocyte Methotrexate Polyglutamates after Low-Dose Methotrexate Therapy in Patients with Rheumatoid Arthritis Clin. Chem., October 1, 2003; 49(10): 1632 - 1641. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. C. Panetta, A. Wall, C.-H. Pui, M. V. Relling, and W. E. Evans Methotrexate Intracellular Disposition in Acute Lymphoblastic Leukemia: A Mathematical Model of {gamma}-Glutamyl Hydrolase Activity Clin. Cancer Res., July 1, 2002; 8(7): 2423 - 2429. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Li, T. J. Ryan, K. J. Chave, and P. Van Roey Three-dimensional Structure of Human gamma -Glutamyl Hydrolase. A CLASS I GLUTAMINE AMIDOTRANSFERASE ADAPTED FOR A COMPLEX SUBSTRATE J. Biol. Chem., June 28, 2002; 277(27): 24522 - 24529. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. D. Cole, B. A. Kamen, R. Gorlick, D. Banerjee, A. K. Smith, E. Magill, and J. R. Bertino Effects of Overexpression of {{gamma}}-Glutamyl Hydrolase on Methotrexate Metabolism and Resistance Cancer Res., June 1, 2001; 61(11): 4599 - 4604. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Volk, K. Rohde, M. Rhee, J. J. McGuire, L. A. Doyle, D. D. Ross, and E. Schneider Methotrexate Cross-Resistance in a Mitoxantrone-selected Multidrug-resistant MCF7 Breast Cancer Cell Line Is Attributable to Enhanced Energy-dependent Drug Efflux Cancer Res., July 1, 2000; 60(13): 3514 - 3521. [Abstract] [Full Text] |
||||
![]() |
K. J. Chave, I. E. Auger, J. Galivan, and T. J. Ryan Molecular Modeling and Site-directed Mutagenesis Define the Catalytic Motif in Human gamma -Glutamyl Hydrolase J. Biol. Chem., December 15, 2000; 275(51): 40365 - 40370. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||